+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban



Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban



Haematologica 103(7): E315-E317




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065465743

Download citation: RISBibTeXText

PMID: 29519861

DOI: 10.3324/haematol.2017.185132


Related references

Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thrombosis and Haemostasis 116(4): 733-738, 2018

Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding. Plos One 8(5): E64112, 2014

Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascular Pharmacology 87: 242-247, 2016

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Advances 1(25): 2320-2324, 2018

Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thrombosis Research 136(4): 749-753, 2016

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thrombosis and Haemostasis 115(02): 424-432, 2016

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. Thrombosis and Haemostasis 115(2): 424-432, 2016

Antiphospholipid sydrome--recurrent thrombosis and foetal loss due to antiphospholipid antibodies. Srpski Arhiv Za Celokupno Lekarstvo 122(5-6): 179-181, 1994

Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban. International Journal of Cardiology 221: 383-384, 2017

A Randomized Trial of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with Antiphospholipid Antibodies. Blood 100(11): Abstract No 555, November 16, 2002

Hypertension is a risk factor of recurrent thrombosis in antiphospholipid antibodies positive systemic lupus erythematodes patients. Lupus 7(SUPPL 2): S224, 1998

Thrombosis of the terminal aorta, deep vein thrombosis, recurrent fetal loss, and antiphospholipid antibodies. Vasa 25(2): 194-199, 1996

Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study. Kardiologia Polska 76(5): 889-898, 2018

Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 23(2 Suppl): I29-I32, 1992

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 24(10): 1087-1094, 2016